In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Recent Study Testing International Formulation Shows Significant Increase in GLP-1 HormoneSALT LAKE CITY, Feb. 04, 2025 ...

DPP-4 inhibitor cases were generally older, more often male, and had lower rates of psychiatric disorders and obesity than GLP-1 RA cases. However, the association between DPP-4 inhibitor use and ...

A recent study from Karolinska Institutet suggests that a type of diabetes medication called GLP-1 agonists could reduce the ...

The risks for disease progression and death were lower for patients with stage 3b or higher CKD receiving GLP-1 RA vs DPP4i ... dipeptidyl peptidase-4 inhibitors (DPP-4i) in male patients with ...

Sarah M. Baxter, from Queen’s University Belfast in Northern Ireland, and colleagues investigated if GLP-1 RA use compared to use of dipeptidyl peptidase-4 inhibitors (DPP-4is) was associated ...